Abstract
BackgroundThe expression of the tissue plasminogen activator gene can be affected by histone deacetylation inhibition and thus appears to be under epigenetic control.ObjectivesThe study aimed to test if in vivo pharmacological intervention by valproic acid treatment would lead to increase in tissue plasminogen activator release capacity.MethodsIn an anaesthetized pig model, a controlled transient coronary occlusion was used to stimulate coronary tissue plasminogen activator release in a valproic acid treated (one week) and a non-treated group. Coronary venous blood samples from the ischemic region were collected, great cardiac vein thermodilution flow measurements were performed, and trans-coronary tissue plasminogen activator fluxes were calculated. Plasminogen activator inhibitor-1 was also measured.ResultsAdequate sampling from the affected area after the 10 minute ischemic period was confirmed by lactate measurements. Fluxes for tissue plasminogen activator at minutes 1, 3, 5, 7 and 10 were measured and then used to present cumulative net tissue plasminogen activator release for the whole measurement period for both groups. Area under the curve was higher for the valproic acid treated group at 10 minutes; 932±173 nanograms (n = 12) compared to the non-treated group, 451±78 nanograms (n = 10, p = 0.023). There was no difference in levels of plasminogen activator inhibitor-1 between groups.ConclusionsThese findings support a proof of concept for histone deacetylation inhibition positive effect on tissue plasminogen activator expression in an in vivo setting. Further studies are needed to find an optimal way to implement histone deacetylation inhibition to achieve desired clinical changes in tissue plasminogen activator expression.
Highlights
Myocardial infarction is most often caused by intravascular thrombus formation, usually at an atherosclerotic lesion
These findings support a proof of concept for histone deacetylation inhibition positive effect on tissue plasminogen activator expression in an in vivo setting
The clinical outcome of the thrombotic event can depend on whether or not the thrombus is rapidly removed by the endogenous fibrinolytic system, or if it persists leading to prolonged regional ischemia and irreversible tissue damage
Summary
Myocardial infarction is most often caused by intravascular thrombus formation, usually at an atherosclerotic lesion. Healthy vascular endothelium produces and stores the key fibrinolytic enzyme, tissue-type plasminogen activator (t-PA). This t-PA is quickly released in the vicinity of the clot when a clotting process is initiated. A number of clinical conditions are associated with a reduced capacity for acute t-PA release, including hypertension, chronic renal failure, obesity and coronary atherosclerosis [8,9,10,11,12]. These are well-established risk factors for myocardial infarction. The expression of the tissue plasminogen activator gene can be affected by histone deacetylation inhibition and appears to be under epigenetic control
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
